Search Results for "New Treatment For Hepatitis B"

20:51 EDT 29th March 2017 | BioPortfolio

Matching Channels

Hepatitis B

Hepatitis A

Hepatitis C

Most hepatitis C virus (HCV) infected individuals seeking treatment are chronically infected. Treatment goal is to achieve a sustained virological response (SVR), which is the absence of serum HCV R...

Hepatitis E virus HEV

Hepatitis B virus HBV

Matching News

Warning: Reactivation of Hepatitis B Virus Coinfection During Treatment of Chronic Hepatitis C Virus Infection

SYNOPSIS: Prior to initiation of hepatitis C virus treatment with direct-acting antivirals, patients should be screened for hepatitis B virus coinfection. Those who are hepatitis B virus-infected shou...

Hepatitis C Treatment Continues to Amaze; Need to Screen Baby Boomers

Regarding the treatment of hepatitis C, I confess that I have been distracted in recent months by the controversy surrounding the cost of treatment and not paid sufficient attention to the incredible ...

Hepatitis C Treatment: Issues for the Emergency Physician

This issue is written to provide you with the knowledge to be able to ask and educate patients with hepatitis C about the highly effective treatment available for most all infected patients.

AbbVie's hepatitis C treatment under accelerated review by EMA

The European Medicines Agency (EMA) has validated AbbVie's marketing authorization application (MAA) for a new hepatitis C treatment.

AbbVie's hepatitis C treatment shows promise

Nov 11 (Reuters) - Drugmaker AbbVie Inc said on Friday its experimental fixed-dose combination to treat certain hepatitis C virus patients achieved high sustained viral response (SVR) rates after eigh...

1 Million-Plus Treated With Highly Effective Hepatitis C Medicines

More than 1 million people in low- and middle-income countries have been treated with a revolutionary new cure for hepatitis C since its introduction two years ago. When direct acting antivirals (DAAs...

EMA Accelerated Assessment for AbbVie's hepatitis C regimen

AbbVie has announced that its investigational, pan-genotypic regimen of Glecaprevir/Pibrentasvir has been awarded Accelerated Assessment by the European Medicines Agency (EMA) for the treatment of all...

The 2017 Hepatitis C Treatment Landscape

Last year, 2016, brought a whirlwind of changes and progress to the hepatitis C field, particularly when it comes to direct-acting antiviral medications. This included various drug approvals and acces...

Matching PubMed Articles

Antiviral treatment and liver-related complications in hepatitis delta.

Hepatitis delta is the most severe form of viral hepatitis. Pegylated interferon alfa (PEG- IFNα) is effective in only 25-30% of patients and is associated with frequent side effects. The aim of this...

Update on Hepatitis C treatment: Systematic review of clinical trials.

Chronic Hepatitis C is a major public health problem. The chronicity of the Hepatitis C can lead to advanced liver disease, cirrhosis and even hepatocellular carcinoma. Chronic hepatitis C is the lead...


Occult hepatitis B infection is characterized by negative hepatitis B surface antigen (HBsAg) and also detectable hepatitis B virus (HBV) -DNA, with or without hepatitis B core antibody (anti-HBc). HB...

On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B.

To investigate potential predictors for treatment response to nucleos(t)ide analogues (NAs) in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients.

Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B.

Previous studies have revealed that hepatitis B core antibody (anti-HBc) levels vary throughout the different phases of treatment-naïve chronic hepatitis B (CHB) patients and can be used as a predict...

Search Whole site using Google

Quick Search
Advertisement Advertisement